Jane Rhodes, Verge Genomics Chief Business Officer

Verge Ge­nomics teams up with As­traZeneca in drug dis­cov­ery deal

Verge Ge­nomics has se­cured its largest deal yet, link­ing up with As­traZeneca’s rare dis­ease di­vi­sion Alex­ion in a deal worth up to $882 mil­lion.

The San Fran­cis­co biotech said Fri­day morn­ing that the four-year deal fo­cus­es on mul­ti­ple undis­closed rare neu­rode­gen­er­a­tive and neu­ro­mus­cu­lar dis­eases. As­traZeneca will pay Verge $42 mil­lion in a mix of an up­front fee, eq­ui­ty and near-term pay­ments, and it’s al­so tak­ing an eq­ui­ty stake in Verge.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.